Work

Comprehensive genomic profiling of ovarian carcinomas identifies both ERBB2 amplifications and activating point mutations as biomarkers for anti-HER2 targeted therapy

Year: 2016

Type: article

Study design: Observational Study

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2016.04.457

Authors: J.A. Elvin, Z.R. Chalmers, J.Y. Hou, G. Del Priore, S.M. Ali, J.A. Vergilio, J. Suh, J. Chmielecki, G. Frampton, D. Lipson, P.J. Stephens, V. Miller, J.S. Ross, J.D. Wright

Institutions: Foundation Medicine (United States), Columbia University, Morehouse School of Medicine, Albany Medical College

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2475726259

FWCI:

Cites:

Cited by:

Related to: 10